跳至主要内容
临床试验/NCT05027737
NCT05027737招募中不适用

Early Ileostomy Closure Following Restorative Proctectomy for Rectal Cancer Patients: A North American Multicenter Randomized-Controlled Trial (RCT)

Jewish General Hospital6 个研究点 分布在 1 个国家目标入组 118 人开始时间: 2022年2月22日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
118
试验地点
6
主要终点
Complications

研究概览

简要总结

Our preliminary work demonstrates that there is buy-in from both patients and surgeons with regards to early ileostomy closure (EIC) for select rectal cancer patients undergoing restorative proctectomy (RP) and diverting loop ileostomy (DLI). The feedback from leaders in Europe further supports the need for a large scale randomized-controlled trial (RCT) on this subject in North America. Should the results of such a study be favourable, we believe it could support a change in practice that would be beneficial to patients and the health care system alike. Furthermore, our work will help identify which patients and practices are suitable for EIC.

The goal of our project is to determine whether EIC in rectal cancer patients undergoing RP with a DLI is safe, feasible and beneficial in a North American population. Specifically, our primary objective is to compare the severity of complications between patients undergoing EIC versus traditional (late) closure. Our secondary objectives include assessing the difference in quality of life (QoL), early and late bowel function, and cost of care between these two groups.

详细描述

Eligible adults (≥18 years-old) from one a large colorectal surgery practice in Canada who (1) underwent RP with creation of a DLI for the treatment of rectal cancer and (2) have a negative anastomotic leak test on post-operative day 7-9 which will consist of a flexible sigmoidoscopy and CT scan with rectally-administered water soluble contrast. Patients will be excluded if there is (1) peri-operative immunosuppression, (2) age-adjusted Charlson Comorbidity Index >6, (3) other major surgery during the index operation, and (4) any major complications (Clavien Dindo Grade III-V) following RP. Eligible participants will be randomized (1:1): Intervention group (EIC): Following a negative leak test, patients will undergo standardized reversal of their DLI (stapled side-side functional end-to end anastomosis, purse-string closure of the ileostomy wound and no use of epidural analgesia) between post-operative days 10-14. Control group (standard practice): Following a negative leak test, patients will undergo a standardized reversal of their DLI no earlier than 12 weeks following their index surgery.

The primary outcome will be comprehensive complication index (CCI) at 12 months following RP. Secondary outcomes will include: CCI at 2-, 6-, and 9-months following RP; recovery from surgery using the PROMIS 29 profile at 7- and 14-days post RP; bowel function, as measured using the Low Anterior Resection Syndrome (LARS) Score at 2-, 6-, 9-, and 12-months post-DLI closure; post-operative ileus, as defined by intolerance to oral intake in the absence of clinical or radiological signs of obstruction, will be measured prospectively after DLI closure; overall QoL, as measured by the EORTC CR30 and QLQ-CR38 at 0-, 2-, 6-, 9-, and 12-months post-RP; cost, as measured from the perspective of the healthcare system [length of hospital stay (RP, ileostomy closure, and any readmissions), interventions in any setting following RP, and appliance-related costs] will be assessed at 6- and 12-months post-index surgery. Treatment effect on the primary outcome (CCI at 12 months) will be modeled using linear regression.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 90 Years(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Adult (≥18 years-old) patients
  • Underwent restorative proctectomy by a laparoscopic, robotic, transanal total mesorectal excision, or open approach with creation of a diverting loop ileostomy for the treatment of rectal cancer
  • Negative anastomotic "leak test" via CT scan with rectally-administered water-soluble contrast on post-operative day 7, 8 or 9.

排除标准

  • Peri-operative immunosuppression (within 6 weeks of surgery date);
  • Age-adjusted Charlson Comorbidity Index >6;
  • Other major surgery during the index operation;
  • Any major complications (Clavien Dindo Grade III or greater) following restorative proctectomy;
  • Inability to speak or comprehend English or French and inability to give informed consent.

结局指标

主要结局

Complications

时间窗: 12-months post-restorative proctectomy

Comprehensive complication index

次要结局

  • EORTC QLQ-CR29 score(Baseline (day of patient recruitment), 2-, 6-, 9-, and 12-months post-restorative proctectomy)
  • Cost of patient care (in dollars)(Calculated at 6- and 12-months post restorative proctectomy)
  • Complications(2-, 6-, and 9-months post-restorative proctectomy)
  • Post-operative recovery(1- and 2-weeks post-restorative proctectomy and diverting loop ileostomy as well as 30 days post-diverting loop ileostomy closure)
  • Occurrence of post-operative ileus following ileostomy reversal(Monitored for from date of ileostomy closure to day of discharge from hospital)
  • Time to chemotherapy (weeks)(Starting from restorative proctectomy post-operative day 1 through the course of the study (1 year follow-up))
  • Bowel function(2-, 6-, 9-, and 12-months post-diverting loop ileostomy closure)
  • EORTC QLQ-C30 score(Baseline (day of patient recruitment), 2-, 6-, 9-, and 12-months post-restorative proctectomy)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Dr. Marylise Boutros

Associate Professor

Jewish General Hospital

研究点 (6)

Loading locations...

相似试验